
==== Front
Ther Adv Neurol Disord
Ther Adv Neurol Disord
TAN
sptan
Therapeutic Advances in Neurological Disorders
1756-2856
1756-2864
SAGE Publications Sage UK: London, England

10.1177/17562864241276847
10.1177_17562864241276847
Letter to the Editor
Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
https://orcid.org/0000-0002-8427-8573
Khouri Charles Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, F-38000 Grenoble, France
HP2, Inserm U1300, Université Grenoble Alpes, Grenoble, France
Conceptualization Writing – original draft
https://orcid.org/0009-0002-8483-5023
Hlavaty Alex Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, Grenoble, France
HP2, Inserm U1300, Université Grenoble Alpes, Grenoble, France
Writing – review & editing
Revol Bruno Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, Grenoble, France
HP2, Inserm U1300, Université Grenoble Alpes, Grenoble, France
Conceptualization Writing – review & editing
Salvo Francesco INSERM, BPH, Team AHeaD, U1219, Université de Bordeaux, Bordeaux, France
Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, Bordeaux, France
Writing – review & editing
Raschi Emanuel Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
Conceptualization Writing – original draft Writing – review & editing
CKhouri@chu-grenoble.fr
12 9 2024
2024
17 175628642412768477 7 2024
2 8 2024
© The Author(s), 2024
2024
SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
disproportionality analysis
drug repurposing
pharmacovigilance
cover-dateJanuary-December 2024
typesetterts1
==== Body
pmcShirani et al. used the US adverse events reporting database to perform a disproportionality analysis and raised repurposing hypotheses regarding the beneficial effect of antidiabetic drugs with weight loss-inducing effects in multiple sclerosis (MS). 1 The results generated considerable interest in the scientific community with echoes in health-related news. 2

Although drug repurposing using adverse event reporting databases represents an emerging research area in pharmacovigilance, we would like to express concern about both results interpretation and methodological aspects. 3 The authors specifically aimed at detecting inverse associations, defined by an upper limit of the 95% confidence interval for reporting odds ratio (ROR) < 1, and suggested a potential for repurposing GLP-1 receptor agonists, SGLT2 inhibitors and metformin in MS, the adverse event of interest. However, the interpretation of a statistically significant negative ROR as inverse causality (i.e. a potential protective effect) is highly controversial for a number of reasons, including the fact that cases collected in these databases are mostly voluntarily reported when a drug is suspected to cause an adverse event (not a beneficial effect) and inherent limitations such as unanticipated reporting biases, lack of certainty on causality, unknown population exposure, and interdependence of disproportionality measures. Therefore, inverse disproportionality signals should rather be described as a lower-than-expected reporting of MS with weight-loss-inducing drugs, especially as the pathophysiological basis linking obesity to MS remains elusive. 4 Moreover, this Brief Report did not fully disclose a number of key methodological issues (e.g. duplicate removal, selection of the comparator) and, importantly, there was neither attempt for diagnosis confirmation nor for controlling biases and confounders (competition bias, channeling bias, co-prescription bias, and confounding by indication), no use of positive/negative controls, lack of sensitivity/robustness analyses (e.g. removing cases where at least one co-reported drug used for MS or having MS as indication was recorded). 5

Innovative methods are needed beyond the mere interpretation of inverse disproportionality signals. For example, the development of methods for matching adverse event profiles and metabolomic or genetic signatures appears promising, since they incorporate a biological rationale.3,6 Moreover, complementing pharmacovigilance data with other sources such as in vitro/in silico testing of drug candidates may allow to prioritize and exclude some biased signals. 7 Exploring drug-induced disorders could represent an additional “bedside to bench” hypothesis-generating approach, especially for neurological diseases with unclear multifactorial etiology such as MS: the identification of drugs plausibly associated with MS sharing targets potentially associated with the development or worsening of the disease may open new avenues for translational studies to investigate relevant disease mechanisms.8,9

In summary, we believe it is still too early to consider antidiabetics as real candidates for MS on the sole basis of an inverse association in disproportionality analysis. Before pursuing further complementary methodologies and prospective studies (as advocated by the authors), a better understanding of the underlying biological basis between obesity and MS, as well as the actual pleiotropic effects of antidiabetics in neuropsychiatric disorders, is warranted.

None.

Declarations

ORCID iDs: Charles Khouri https://orcid.org/0000-0002-8427-8573

Alex Hlavaty https://orcid.org/0009-0002-8483-5023

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Author contributions: Charles Khouri: Conceptualization; Writing – original draft.

Alex Hlavaty: Writing – review & editing.

Bruno Revol: Conceptualization; Writing – review & editing.

Francesco Salvo: Writing – review & editing.

Emanuel Raschi: Conceptualization; Writing – original draft; Writing – review & editing.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests: The authors declare that there is no conflict of interest.

Availability of data and materials: Not applicable.
==== Refs
References

1 Shirani A Cross AH Stuve O. Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. Ther Adv Neurol Disord 2024;17 :17562864241241383.
2 Altmetric. Altmetric database in JSON format. Unpublished raw data , https://sage.altmetric.com/details/161543995 (2024)
3 Morris R Ali R Cheng F. Drug repurposing using FDA Adverse Event Reporting System (FAERS) database. Curr Drug Targets 2024; 25 (7 ): 454–464.38566381
4 Cutroneo PM Sartori D Tuccori M , et al . Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul 2024; 3: 1323057 .
5 Fusaroli M Salvo F Begaud B , et al . The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 2024; 47 (6 ): 585–599.38713347
6 Zaza P Matthieu R Jean-Luc C , et al . Drug repurposing in Raynaud’s phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. Br J Clin Pharma 2020; 86 : 2217–2222.
7 Chrétien B Jourdan J Davis A , et al . Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer’s disease. Br J Clin Pharma 2021; 87 : 2830–2837.
8 Antonazzo IC Raschi E Forcesi E , et al . Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. Expert Opin Drug Saf 2018; 17 : 869–874.30058390
9 Gaimari A Fusaroli M Raschi E , et al . Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System. Drug Saf 2022; 45 : 663–673.35610460
